AbCellera acquires transmembrane protein producer; Compass gains psychedelic IP portfolio
Canadian antibody shop AbCellera acquired Massachusetts biotech TetraGenetics in an all-cash transaction. While more specific details were not made publicly available, AbCellera did say in a statement that the acquisition includes an upfront payment and potential milestone payments based on technical achievements, successful R&D and commercialization.
Founded in 2004, TetraGenetics specializes in protein production — specifically transmembrane proteins, which have proven to be difficult to produce in the past. Where TetraGenetics comes into the equation with AbCellera is that TetraGenetics can make enough transmembrane proteins to support antibody discovery.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.